alexa Abstract | Synthesis and studies of novel piperidine-substituted triazine derivatives as potential anti-inflammatory and antimicrobial agents

Journal of Chemical and Pharmaceutical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Original Articles Open Access


A series of some novel 2,4-dimethoxy-6-(piperazin-1-yl)-1,3,5-triazine aryl ureido/aryl amido derivatives of biological interest were prepared and screened for their pro-inflammatory cytokines (TNF-α and IL-6) and antimicrobial activity. Among all the series of compounds screened, the compounds 5c, 5f, 6c, and 6f were found to have promising anti-inflammatory activity (up to 65–73% TNF-α and 73–85% IL-6 inhibitory activity) at concentration of 10 μM with reference to standard dexamethasone (75% TNF-α and 84% IL-6 inhibitory activities at 1μM) while the compounds 5a, 5d, 5e, 6a and 6e found to be potent antimicrobial agent showing even 2 to 2.5- fold more potency than that of standard ciprofloxacin and miconazole at the same MIC value of 10 μg/mL.

To read the full article Peer-reviewed Article PDF image

Author(s): Ravindra S Shinde and Shridhar D Salunke


1,3,5-triazine, piperazine, aryl urea and amide, anti-inflammatory activity, antimicrobial activity., antimicrobial

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version